If you've just been injured, or you love someone who has, this is the question that matters most. You'll find two kinds of bad answers online: breathless "paralysis cured!" headlines, and bleak "nothing will ever change" cynicism. Neither is accurate.

Here is the honest version, current as of October 2026, with sources you can check.

🧭
The short answer: No therapy yet reverses a chronic spinal cord injury — nothing on the market or in trials regrows the cord back to normal. But the last two years produced something real: the first FDA-authorized device that restores hand function after chronic SCI, the first human stem-cell results showing measurable movement gains (now with four years of safety follow-up), and brain-and-spine technology that let paralyzed people walk and control computers by thought. The accurate story isn't "a cure is here" or "nothing works." It's steady, multi-front progress that restores function — not a single cure around the corner.

Why This Question Is So Hard to Answer

SCI research moves on several separate tracks at once — stimulation, brain implants, cell transplants, drugs, and regeneration biology — and they're at wildly different stages. Some are FDA-authorized and in clinics today; some are dazzling results in a single person; some are still only in mice; and several heavily promoted drugs have outright failed their big trials. Lumping them together as "the cure" is exactly how hope gets exploited. So this article sorts every approach by how far along it actually is.

First: What "Cure" Even Means

Researchers and the major foundations have largely stopped using "cure" to mean "regrow the cord to exactly how it was." That isn't close, and no credible scientist claims it is. Instead, the working goal is restoring meaningful function — and which function often matters more to people living with SCI than walking does: hand and arm use, bladder and bowel control, stable blood pressure, sexual function, less spasticity and pain. Several of those are advancing faster than "walking again." Keep that reframing in mind every time you read the word "cure."

What's Actually Available Now

Only a short list of things in this entire article are FDA-authorized and usable today. Everything else is a research study.

ARC-EX (ONWARD Medical) — the genuine 2024 milestone. In December 2024 the FDA granted De Novo authorization to the ARC-EX System — the first non-invasive spinal cord stimulation device cleared for chronic SCI. Electrodes on the skin over the back of the neck deliver stimulation paired with rehab to improve hand strength and sensation in people with chronic, incomplete tetraplegia. In the pivotal Up-LIFT trial of 65 participants (published in Nature Medicine), about 90% improved in strength or function and most reported better quality of life. In November 2025 the FDA expanded the clearance to home use, and by September 2026 ONWARD reported it was available in more than 130 US clinics, with the first systems sold to individuals for home use — including through the VA healthcare system. Two honest caveats: this is a De Novo authorization, not a full PMA "approval," and it improves function — it does not repair the cord.

ExaStim (ANEUVO) — a second non-invasive device, cleared in 2026. In April 2026 the FDA cleared ANEUVO's ExaStim, a portable transcutaneous (skin-surface, non-implanted) spinal cord stimulation system. Like ARC-EX, it is indicated to improve hand sensation and strength in adults (18–75) with chronic, incomplete SCI when paired with functional task practice, and it is cleared for both clinic and home use (it had carried a European CE Mark since April 2025). In August 2026 a federal-contracting partnership made it orderable for veterans through the VA system. It gives people a second FDA-cleared non-invasive option — but, like ARC-EX, it restores function and does not repair the cord.

Functional electrical stimulation (FES). The decades-old, widely available workhorse of rehab: electrical current applied to muscles or nerves to produce useful movement — grasp, FES cycling, standing, cough and bladder assist. A 2025 review of 23 randomized trials found FES meaningfully improves respiratory function. It's increasingly combined with the newer spinal-stimulation and brain-implant approaches below.

✅
The practical takeaway: if a clinic offers you anything other than these as an available "treatment" — especially if you have to pay for it — you're looking at research (at best) or a scam (at worst). Skip to the stem-cell section for why that matters.

Spinal Stimulation and the Brain–Spine "Digital Bridge"

This is the fastest-moving and most credible area — not because it heals the cord, but because it reactivates circuits that survive below the injury.

Epidural stimulation (research programs). Implanted electrodes on the surface of the cord, paired with intensive training, have let people with chronic SCI in programs at the University of Louisville (Harkema/Angeli) and Mayo Clinic recover voluntary movement, and stand or step with assistance. A 2024 systematic review found that across pooled participants, many achieved assisted standing or stepping and improved walking — encouraging and directionally reproducible, but built on small cohorts with varied protocols. These remain research-only (no FDA approval for this use).

Restoring autonomic function — the underrated story. The same stimulation is being aimed at problems that affect daily life more than walking. ONWARD's implanted ARC-IM system targets the dangerous blood-pressure instability many people face after SCI; in September 2025, papers in Nature and Nature Medicine reported it produced immediate, durable blood-pressure stabilization in early participants, and in August 2025 the FDA approved the IDE for its Empower BP pivotal trial, which enrolled its first participant in February 2026 (at Craig Hospital in Denver). By September 2026, 22 participants had been enrolled across 14 actively recruiting sites in the US and Canada, with roughly 20 centers planned across North America and Europe; it is randomized, double-blinded, and sham-controlled — the kind of design that can actually prove benefit. ONWARD has also started EIGER, a small Swiss feasibility study using ARC-IM to support standing and walking after subacute or chronic injury, and says a first-in-human study of ARC-IM for bladder function is next. Epidural-stimulation groups have similarly reported gains in bladder, bowel, and temperature regulation. ARC-IM is still investigational.

The brain–spine "digital bridge." In 2023, the NeuroRestore team (Courtine and Bloch) published in Nature a wireless system linking brain implants that decode intention to move to electrodes stimulating the spinal cord — a "digital bridge" that let a paralyzed man, Gert-Jan Oskam, stand, walk, and climb stairs under his own volition, reliably for over a year. It's a landmark. The published result is still a single-participant proof of concept, but it is now being extended: ONWARD, which is commercializing the approach as ARC-BCI, reported in September 2026 that seven people with SCI had received the brain-plus-spine implant in ongoing feasibility studies. Outcomes for that larger group haven't been published yet, and it remains investigational — not a product.

Brain–Computer Interfaces

BCIs read signals directly from the brain to control a cursor, a device, a robotic arm, or synthesized speech. For high-level injuries they can restore communication and digital independence — but it's worth being clear-eyed: a BCI routes around the injured cord; it doesn't repair it, and every system below is investigational.

  • Neuralink (PRIME study). A fully implanted, wireless brain implant. The first participant, Noland Arbaugh (cervical SCI), was implanted in January 2024 and uses it to control a computer — browsing, gaming, design — by thought. By fall 2026 it had reportedly been implanted in more than two dozen people (participants' own tallies put it around 26–27, including a UK cohort) across several countries; no single official running total exists, so treat the exact count as approximate. In September 2026 Neuralink released video from its companion speech study (VOICE) of a participant with bulbar-onset ALS saying "I love you" to his wife through synthesized speech decoded from his brain — a striking demonstration, though a video of one person is not a published result. An important, openly reported setback: in the first participant many of the implant's threads retracted from the brain in the weeks after surgery, degrading performance until software changes recovered much of it. The FDA granted Neuralink a breakthrough-device designation for speech restoration in May 2025.
  • Synchron (Stentrode). A cleverly less-invasive approach: the implant is threaded through a blood vessel to rest over the motor cortex — no open-brain surgery. About a dozen people have been implanted (its COMMAND study); the company raised a $200M Series D in November 2025 to fund a pivotal trial — the study it must clear before seeking the first FDA approval of an implantable BCI — with development partnerships including NVIDIA and Apple. As of fall 2026 it was still finalizing that trial's design with the FDA and had opened a patient registry; a pivotal start hadn't been announced.
  • Precision Neuroscience. Its thin-film "Layer 7" cortical array received FDA 510(k) clearance in 2025 — but as a research/monitoring tool for up to 30 days, not yet a take-home assistive BCI. In September 2026 it closed a $250M Series D and reported more than 100 patient procedures across 18 hospitals (mostly short-term recordings during surgery), with the money earmarked for the next stages of FDA review toward a long-term implant.
  • BrainGate / Blackrock. The ~20-year academic consortium that established the entire field — cursor, robotic-arm, handwriting, and speech decoding in people with paralysis. Still research, but the bedrock everyone else builds on.
  • Speech neuroprostheses. In March 2025, a UCSF/UC Berkeley team reported a system that synthesized near-real-time speech from brain signals in a woman who hadn't spoken in years — directly relevant to the most severe high-cervical injuries.

Stem Cells and Cell Therapy

This is the track most people mean by "cure" — replacing or supporting lost cells in the cord — and it's also the most contaminated by hype and outright fraud. Here's where the legitimate science actually stands. The honest summary: real but small, mostly early-phase, and mostly demonstrating safety rather than proven recovery.

  • iPS-cell transplant (Keio University, Japan) — the headline human result. In a world-first trial, researchers transplanted about 2 million neural cells (made from reprogrammed "induced pluripotent" stem cells) into the cords of four people with recent, complete injuries. Reported in 2025: no serious adverse events, and 2 of the 4 improved in motor function — one regained enough movement to practice walking, one to eat independently; the other two didn't change. In July 2026 the full results were published in Nature Medicine with up to four years of follow-up: no tumors and no serious adverse events attributed to the cells, and the team reported that motor gains and AIS-grade improvement at one year exceeded a historical comparison group. The team plans an investigator-initiated trial in chronic, incomplete injury, expected to begin recruiting around 2027. A real milestone — and still four patients, uncontrolled, in injuries where some spontaneous recovery can occur. It's a first step, not a proven therapy.
  • OPC1 (Lineage Cell Therapeutics). Oligodendrocyte progenitor cells (formerly the Geron/Asterias program), with FDA RMAT designation. The DOSED study, begun in 2025, is mainly testing a new spinal delivery device and safety, including in chronic injuries; by 2026 it had expanded to a second site and its first chronic-injury participants had passed their early safety follow-ups without device-related problems. Earlier studies suggested arm/hand gains but were uncontrolled.
  • Schwann cells (Miami Project). Phase 1 trials using a patient's own Schwann cells were completed with a good safety profile — but they establish safety and feasibility only, not proven recovery.
  • Mesenchymal stem cells — Mayo CELLTOP. In 10 people, intrathecal injections of the patient's own fat-derived MSCs were safe and 7 of 10 improved at least one grade on the injury scale (Nature Communications, 2024). Promising — but single-arm, no placebo, and grade improvement is exactly the outcome most prone to false positives. Broader reviews still call clinical translation of stem-cell therapy "premature."
⚠️
This is the most important paragraph here. Legitimate cell-therapy trials are run under regulatory oversight and are free to participants. Offshore clinics charging $20,000–$100,000+ for "stem cell treatments" have no evidence of benefit for SCI and have caused real harm — infection, tumors, neurological worsening, death. If you're paying for it, it isn't the research described above. See Stem Cells & Peptides for SCI and Avoiding Scams After SCI.

Drugs to Protect or Regrow the Cord — Including the Disappointments

Accuracy means reporting failures, not just press releases. The drug track has been humbling:

  • Riluzole (RISCIS). A Phase 3 trial in acute injury did not meet its primary endpoint — though it was cut short during COVID and left underpowered, and a later reanalysis argued for an overall effect. Net: inconclusive/negative.
  • Anti-Nogo antibody (NISCI). A Phase 2b trial (Lancet Neurology, December 2024) missed its primary endpoint; it was safe and hinted at benefit in a subgroup of incomplete injuries, but that's hypothesis-generating only.
  • HGF / KP-100 (Kringle Pharma). Its Phase 3 trial also missed the primary endpoint (reported February 2024), with only secondary signals.
  • Minocycline showed a non-significant trend in Phase 2. Elezanumab (AbbVie), an antibody given within 24 hours of acute cervical injury, finished its Phase 2 trial in early 2026 — but as of October 2026 the results still hadn't been reported, and the same drug already failed in multiple sclerosis, tempering expectations.
  • Polymerized laminin — a new entrant to watch, carefully. In August 2026 a Brazilian group published a first-in-human pilot (Spinal Cord) in which a single injection of a scaffold-forming protein was placed directly into the cord of eight people with acute, complete (AIS A) injuries, within days of trauma. The injection itself caused no problems, and six of the eight later regained some voluntary movement (converting to AIS C or D). Read that with every caveat available: no control group, acute injuries where early AIS conversion sometimes happens on its own, three participants died during follow-up of causes judged unrelated, and the study began before trial pre-registration was required. The authors themselves say it "does not allow conclusions regarding efficacy" — it justifies a controlled trial, nothing more yet.
  • NervGen NVG-291 — the bright spot, and it strengthened this year. Its placebo-controlled CONNECT SCI trial (20 people with chronic injury, averaging ~3.5 years post-injury) first reported in June 2025 that it hit a nerve-connectivity biomarker endpoint while hand function only trended positive. But expanded data released afterward showed a durable, clinically meaningful hand-function gain — roughly a 3.7-fold greater improvement than placebo on the GRASSP prehension measure at week 16, still increasing a month after dosing had stopped. A separate blinded gait analysis released in May 2026 reported better walking coordination and stability in treated participants, too. In April 2026 NervGen reached FDA alignment on RESTORE, a Phase 3 registrational trial (~150 people with chronic cervical injury, 1–10 years out, at up to 60 US and Canadian sites; 12 weeks of daily injections; hand function as the primary endpoint). The trial is currently recruiting at sites across the US and Canada, with enrollment expected to finish in late 2027 and topline results expected in the first half of 2028 — so the answer is roughly 18 months away. Encouraging, with a real timeline now — but it is still only 20 people so far, and Phase 3 is exactly where hopeful SCI drugs have repeatedly failed.

The Breakthroughs That Are Real — But Still in Animals

The most spectacular "regrew the cord, restored walking" headlines are true — in mice. They matter because they teach us how repair could work, but the leap from rodent to human in SCI has failed far more often than it has succeeded, so read these as foundations, not imminent treatments.

  • The "regeneration recipe" (Courtine lab, Science 2023). In mice with complete injuries, regrowing nerve fibers and chemically guiding them to their natural targets restored walking — while regrowth without guidance did nothing. A landmark insight: direction matters, not just growth. Preclinical.
  • "Tabulae Paralytica" (Nature 2024). A detailed molecular atlas of the injured cord that identified the cell states governing repair, plus a gene therapy that restored walking in mice. A map for future human targets. Preclinical.
  • A human spinal-cord "organoid" repair model (Nature Biomedical Engineering, 2026). Northwestern's Stupp lab grew a lab-dish human spinal-cord "mini-organ" — the first to include the cord's resident immune cells — injured it, and showed their injectable "dancing molecules" therapy shrank scar tissue and regrew nerve fibers, echoing an earlier mouse result. The therapy has FDA Orphan Drug designation. Still preclinical — tissue in a dish, not a living person.
  • Biomaterial scaffolds show promise bridging the injury site in animals, but none has reversed chronic human SCI.

So — Is a Cure Close?

Holding all of it honestly:

  • A cure that reverses a chronic spinal cord injury is not close. No approved therapy and no current trial regrows the cord to normal, and credible timelines for new cell or regenerative therapies reaching the clinic run into the late 2020s and 2030s — contingent on trials that have, so far, more often failed than succeeded.
  • Functional restoration, however, is real and accelerating. The fastest, most credible progress is in neuromodulation plus rehabilitation — and 2024–2025 delivered the first FDA-authorized device (ARC-EX), real blood-pressure results, and thought-controlled movement and communication. These change lives without "curing" paralysis.
  • The honest shape of it: a handful of small but real human signals (Keio iPS cells now with four-year safety data, NervGen's hand-function data entering a Phase 3 that reads out around 2028, MSC and OPC1 safety, an uncontrolled laminin pilot), a string of failed or underpowered drug trials, and astonishing regeneration science that's still in animals.
  • Be skeptical of anyone selling certainty — in either direction. The foundations driving this work, including the Reeve Foundation, consistently warn against both "cure is around the corner" framing and the paid stem-cell clinics that exploit it.

What this means for you practically: the legitimate way to access tomorrow's therapies is through registered clinical trials, which are free to join. You can search recruiting SCI studies in our Clinical Trials Finder (updated daily from ClinicalTrials.gov data), and learn how to evaluate any specific approach in Clinical Trials & SCI Research, Honestly. For the stimulation devices specifically, see Spinal Cord Stimulators.

Sources & Further Reading

Research current to October 2026. This field moves fast — verify the latest at pubmed.gov and in our daily-updated Clinical Trials Finder.

Stimulation & brain–spine interface

Brain–computer interfaces

Cell therapy, drugs & regeneration

SCI.help articles are information, not medical advice. Research status changes quickly; confirm anything you're considering with your care team and verify a trial's standing before enrolling. Legitimate trials don't charge you a fee to enroll or for the experimental treatment itself (though you may still have routine copays or travel costs).

Related reading

Research
Stem Cells & Peptides: What the Research Shows
Research
Spinal Cord Stimulators
Medical
Clinical Trials & SCI Research, Honestly
Medical
Will I Recover? Prognosis & Realistic Hope
Medical
Avoiding Scams After SCI
Tool
Clinical Trials Finder

Heard about a treatment and want to evaluate it?

Share what you've found. Honest, sourced information is how we protect each other from hype.

Share what you've learned →
Based on published research, FDA actions, and company disclosures as of October 2026. The field moves fast — verify recent developments at pubmed.gov and in our Clinical Trials Finder (updated daily). · Last reviewed October 2026